Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06308718 · ClinicalTrials.gov registry record
Long-term Follow-up Study to Evaluate Safety and Efficacy of FBX-101 in Krabbe Patients
A clinical trial, sponsored by Forge Biologics.
- Terminated
- Registry status
- 2
- Enrollment target
NCT06308718 is a clinical trial that was terminated before completion, run by Forge Biologics. The registered enrollment target is 2 participants.
The verdict
NCT06308718 was terminated before completion, sponsored by Forge Biologics.
- TERMINATED
- Registry status
- 2 participants
- Enrollment target
Study Summary
This is an observational study that will enroll any patients with Krabbe disease that have participated in prior interventional clinical trials involving the administration of FBX-101.
Interventions
- BIOLOGICAL FBX-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2024-08-06 |
| Est. Completion | 2025-04-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06308718
The ClinicalTrials.gov registry entry for NCT06308718 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Forge Biologics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which FBX-101 is the first listed.
NCT06308718 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06308718 about?
NCT06308718 is a clinical study titled "Long-term Follow-up Study to Evaluate Safety and Efficacy of FBX-101 in Krabbe Patients". This is an observational study that will enroll any patients with Krabbe disease that have participated in prior interventional clinical trials involving the administration of FBX-101.
What is the current status of trial NCT06308718?
This trial is currently terminated. The enrollment target is 2 participants. The study started on 2024-08-06. Estimated completion is 2025-04-11.
What interventions are being tested in trial NCT06308718?
The interventions under investigation include: FBX-101 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06308718?
This trial is sponsored by Forge Biologics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.